Deals, Partnering

EnVivo Pharmaceuticals and Mitsubishi Tanabe Pharma enter license agreement on EVP-6124 in Japan, Korea, Taiwan and other Asian countries

Posted on 01 April 2009

Tags: ,

MTPC has obtained exclusive rights to develop and commercialize EnVivo's alpha-7 nicotinic acetylcholine receptor agonists such as EVP-6124 in Japan, Korea, Taiwan, Indonesia and several other Asian markets. MTPC plans to initiate Phase I clinical trials within 2010. EnVivo will receive an initial license payment and is eligible for clinical and regulatory milestones, as well as several commercial milestones. EnVivo also will receive royalties on sales of EVP-6124 in the MTPC territory.

Print Friendly, PDF & Email

Leave a Reply